Sysmex Inostics specializes in purpose-designed, ultra-sensitive tests capable of detecting genetic alterations at very low mutant allele frequencies.
Our SafeSEQ and OncoBEAM™ testing services help ensure the most efficient approach to patient enrollment in clinical trials for targeted therapies through reliable identification of even the lowest frequency mutations.
SafeSEQ and OncoBEAM™ technologies are ideal for exploring novel clinical applications that require ultra-high sensitivity, such as molecular monitoring of disease progression, identification of targetable resistance alterations, and detection of minimal residual disease.
SafeSEQ Next-Generation Sequencing (NGS) services offer exquisite sensitivity, with reliable detection of 5 mutant molecules in a background of 10,000 wildtype molecules (0.05% MAF). We offer expert-designed panels to answer your clinical questions accurately and efficiently.
Detect important mutations from 0.02% to 0.04% allele frequency using BEAMing enhanced digital PCR technology. OncoBEAM tests are highly clinically validated across numerous disease types to ensure unrivaled depth of information from a simple blood draw.
Choose your genes and mutations of interest with fast delivery of a custom NGS-based SafeSEQ panel to answer critical clinical questions.
Germany: Sysmex Inostics GmbH, Falkenried 88, D-20251 Hamburg, Germany. +49 40- 325907-0
United States: Sysmex Inostics, Inc., 1812 Ashland Ave Suite 500, Baltimore, Maryland 21205, USA. +1-855-BEAM-DNA (232-6362)
Japan: Sysmex Corporation, 1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan. +81 78 265-0500